Good morning one and all. Nice to see you again. 'Tis the middle of the week, which means we are in the thick of those meetings and deadlines. To cope - yes - we are brewing some cups of stimulation. Two-fisted drinking is possible even while manipulating a laptop. Feel free to join us. And we would also like to invite you to awebinar we are hosting next week on disclosing physician payments. Meanwhile, here are some interesting tidbits. Have a productive day and stay in touch...
Novartis COPD Drug Gets Mixed FDA Panel Verdict (Wall Street Journal)
J&J Misled South Carolina About Risperdal, Lawyer Says (Bloomberg News)
Combo Diet Pills Making A Comeback (MSNBC)
Human Genome Lupus Drug Expected To Be Approved (Reuters)
Glaxo Withdraws Sports Drink Over Mold Growth (The Grocer)
Proposed EU Patent Court Not Compatible With EU Law (Pharma Times)
CVS Faces Class Action Suit For Selling Prescription Data (Courthouse News)
McKesson Faces Class Action Suit Over Price Fixing (Business Insurance)
Glaxo Invests In Sri Lankan Plant (InPharma Technologist)
Salix IBS Drug Gets Bounced By FDA (MedCity News)
Coffee pix thx to chichcacha flickr creative commons
1 Comment
If you dig the idea of your next child being born with cleft palate go ahead and do phen-Topomax. Afterwards you may need a combo antidepressant to get back to normal.
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm245777.htm